1. Home
  2. Labeler Index
  3. Cipla Usa Inc.
  4. 69097-098
  5. NDC Package Code: 69097-098-08 Amoxicillin And Clavulanate Potassium

NDC Package 69097-098-08 Amoxicillin And Clavulanate Potassium

Suspension Oral - View Billable Units, 11-Digit Format, RxNorm

Table of Contents

    1. Package Information
    2. Other Packages
    3. Frequently Asked Questions

Package Information

Find all the important details about this NDC Package code, including the 11-Digit NDC Billing number, billing units, wholesale price, RxNorm crosswalk, active ingredients, pharmacologic clasess, etc.

NDC Package Code:
69097-098-08
Package Description:
150 mL in 1 BOTTLE
Product Code:
69097-098
Proprietary Name:
Amoxicillin And Clavulanate Potassium
Non-Proprietary Name:
Amoxicillin And Clavulanate Potassium
Substance Name:
Amoxicillin; Clavulanate Potassium
Usage Information:
Amoxicillin and clavulanate potassium for oral suspension is indicated for the treatment of infections in adults and pediatric patients, due to susceptible isolates of the designated bacteria in the conditions listed below:Lower Respiratory Tract Infections - caused by beta-lactamase–producing isolates of Haemophilus influenzae and Moraxella catarrhalis.Acute Bacterial Otitis Media - caused by beta-lactamase–producing isolates of H. influenzae and M. catarrhalis.Sinusitis - caused by beta-lactamase–producing isolates of H. influenzae and M. catarrhalis.Skin and Skin Structure Infections - caused by beta-lactamase–producing isolates of Staphylococcus aureus, Escherichia coli, and Klebsiella species.Urinary Tract Infections - caused by beta-lactamase–producing isolates of E. coli, Klebsiella species, and Enterobacter species.Limitations of UseWhen susceptibility test results show susceptibility to amoxicillin, indicating no beta-lactamase production, amoxicillin and clavulanate potassium for oral suspension should not be used.UsageTo reduce the development of drug-resistant bacteria and maintain the effectiveness of amoxicillin and clavulanate potassium for oral suspension and other antibacterial drugs, amoxicillin and clavulanate potassium for oral suspension should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
11-Digit NDC Billing Format:
69097009808
Billing Unit:
ML - Billing unit of "milliliter" is used when a product is measured by its liquid volume.
NDC to RxNorm Crosswalk:
150 ML
NDC to RxNorm Crosswalk:
  • RxCUI: 617322 - amoxicillin 250 MG / clavulanic acid 62.5 MG in 5 mL Oral Suspension
  • RxCUI: 617322 - amoxicillin 50 MG/ML / clavulanate 12.5 MG/ML Oral Suspension
  • RxCUI: 617322 - amoxicillin (as amoxicillin trihydrate) 250 MG / clavulanic acid (as clavulanate potassium) 62.5 MG per 5 Oral Suspension
  • RxCUI: 617322 - amoxicillin 250 MG / clavulanic acid 62.5 MG per 5 ML Oral Suspension
Product Type:
Human Prescription Drug
Labeler Name:
Cipla Usa Inc.
Dosage Form:
Suspension - A liquid1 dosage form that contains solid particles dispersed in a liquid vehicle.
Administration Route(s):
Oral - Administration to or by way of the mouth.
Active Ingredient(s):
Pharmacologic Class(es):
Sample Package:
No
FDA Application Number:
ANDA065431
Marketing Category:
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date:
10-28-2024
Listing Expiration Date:
12-31-2025
Exclude Flag:
N
Code Structure:

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the disclaimer below.

Other Product Packages

The following packages are also available for this product:

NDC Package CodePackage Description
69097-098-4375 mL in 1 BOTTLE
69097-098-44100 mL in 1 BOTTLE

* Please review the disclaimer below.

Frequently Asked Questions

What is NDC 69097-098-08?

The NDC Packaged Code 69097-098-08 is assigned to a package of 150 ml in 1 bottle of Amoxicillin And Clavulanate Potassium, a human prescription drug labeled by Cipla Usa Inc.. The product's dosage form is suspension and is administered via oral form.

Is NDC 69097-098 included in the NDC Directory?

Yes, Amoxicillin And Clavulanate Potassium with product code 69097-098 is active and included in the NDC Directory. The product was first marketed by Cipla Usa Inc. on October 28, 2024 and its listing in the NDC Directory is set to expire on December 31, 2025 if the product is not updated or renewed by the manufacturer.

What is the NDC billing unit for package 69097-098-08?

The contents of this package are billed per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume. The calculated billable units for this package is 150.

What is the 11-digit format for NDC 69097-098-08?

The 11-digit format is 69097009808. The 11-digit billing format might be required by the Centers for Medicare & Medicaid Services (CMS) and other payers in billing claim forms.

This package code is originally configured in a 5-3-2 segment 10-digit format and by adding a zero within the original NDC package code we can obtain the converted 11-digit format in a 5-4-2 segment configuration. The table below shows the 11-digit code conversion:

10-Digit Format10-Digit Original Code11-Digit Format11-Digit Code
5-3-269097-098-085-4-269097-0098-08